Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 13

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 13
---
arket
Sales Agreement (the “Amended and Restated Sales Agreement”) with RBC Capital Markets, LLC and BTIG, LLC as sales agents pursuant
to which we may offer and sell, from time to time, in its sole discretion, shares of its common stock, having an aggregate offering price
of up to $75,000,000, subject to certain limitations on the amount of common stock that may be offered and sold by us set forth in the
Amended and Restated Sales Agreement.

We filed with the SEC a prospectus supplement dated
August 9, 2024, specifically relating to offers and sales of common stock under the Amended and Restated Sales Agreement (the “ATM
Prospectus Supplement”), together with the prospectus forming a part of Registration Statement. As of the date of this prospectus
supplement, we have sold an aggregate of (i) $2,095,293 of shares of our common stock pursuant to Amendment No. 1 to the Sales Agreement,
(ii) $16,298,838 of shares of our common stock pursuant to the Sales Agreement, all of which were sold prior to the execution of Amendment
No. 1 to the Sales Agreement and (iii) $3,878,225 of shares of our common stock pursuant to the Amended and Restated Sales Agreement.

Cordstrom License

On February 6, 2025, the Company and GOSH entered
into a license agreement for the exclusive commercial use to clinical trial data associated with the Mission EB study investigating the
potential of CORDStrom to treat RDEB in pediatric patients. The Company owns the intellectual property covering CORDStrom, the investigational
medicinal product used in the Mission EB study. In addition, the Company owns intellectual property and maintains trade secret protections
covering the manufacturing of CORDStrom. With this license to the clinical trial data, the Company intends to prepare applications seeking
marketing authorization of CORDStrom for treatment of pediatric RDEB in each of the FDA, EMA, and MHRA. Terms of the license agreement
include an upfront payment of £250,000 (approximately $0.3 million) and a single milestone payment of up to £6,000,000 (approximately
$7.8 million) due on the first to occur marketing authorization to be granted by the FDA, EMA or MHRA. In addition to these financial
terms, the Company has also agreed to certain patient access obligations